Marks Group Wealth Management Inc Acquires 167 Shares of Zoetis Inc. (NYSE:ZTS)

Marks Group Wealth Management Inc increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,643 shares of the company’s stock after acquiring an additional 167 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Zoetis were worth $2,495,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Zoetis by 7.4% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after buying an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC acquired a new position in Zoetis during the 4th quarter worth approximately $2,776,000. BLB&B Advisors LLC lifted its stake in Zoetis by 1.9% in the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock valued at $10,591,000 after purchasing an additional 1,107 shares during the last quarter. Ninety One UK Ltd boosted its position in Zoetis by 13.1% in the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock valued at $21,374,000 after buying an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Zoetis by 10.9% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after buying an additional 17,976 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 2,209 shares of company stock valued at $371,293 over the last 90 days. Company insiders own 0.15% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. The Goldman Sachs Group raised their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Stifel Nicolaus reduced their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $218.00.

Zoetis Trading Up 2.5 %

Zoetis stock traded up $3.57 during mid-day trading on Tuesday, hitting $149.11. 2,140,539 shares of the stock were exchanged, compared to its average volume of 3,039,154. The firm’s fifty day simple moving average is $174.45 and its two-hundred day simple moving average is $179.97. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock has a market capitalization of $68.20 billion, a price-to-earnings ratio of 29.35, a PEG ratio of 2.24 and a beta of 0.85.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.15 EPS. Analysts forecast that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.16%. Zoetis’s payout ratio is 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.